Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option Jan 31, 2024 4:01pm EST
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical Jan 26, 2024 8:00am EST
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting Dec 09, 2023 6:30pm EST
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role Nov 30, 2023 4:59pm EST
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting Nov 02, 2023 9:00am EDT
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib Oct 30, 2023 9:15am EDT
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 Oct 26, 2023 7:11am EDT
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th Oct 23, 2023 7:30am EDT
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference Oct 16, 2023 7:30am EDT
